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Abstract: Three separate theories of inhibiting cisplatin-induced apoptosis were investigated 
utilizing different cellular mechanisms. Specifically, the copper transport cycle, TRPV1, and 
the JNK pathway were inhibited and immunohistochemistry was performed to determine levels 
of apoptosis. All three resulted in statistically significant effects; increasing CuSO4 levels 
resulted in increased apoptosis, and inhibiting TRPV1 and JNK resulted in decreased 
apoptosis.    
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Background 
Cis-diamminedichloroplatinum, or cisplatin, is an antineoplastic agent commonly used 
for the treatment of a variety of cancers; including testicular, ovarian, bladder, cervical, head and 
neck, and non-small cell lung cancers. The dose-limiting effects of cisplatin are well-documented 
and include nephrotoxicity, emetogenesis, and ototoxicity (Wang & Lippard, 2005; Rybak et al., 
2007). Ototoxic effects (such as tinnitus and high-frequency hearing loss) have been reported in 
approximately 30% of treated individuals (Nagy et al., 1999). It has been demonstrated that 
cisplatin not only promotes apoptosis in auditory cells (van Ruijven et al., 2005), but also 
vestibular cells (Slattery & Warchol, 2010). While much research has been conducted on the 
mechanisms of cisplatin ototoxicity, it remains a significant clinical problem. There continues to 
be a need for refinement and additional research on the cellular uptake and method of action of 
cisplatin 
Copper Uptake as a factor in ototoxicity 
Studies have shown that cisplatin-resistant cell lines exhibit a cross-resistance to copper 
efflux, indicating a potential connection between copper transporters and cisplatin intake in cells 
(Matsumoto et al., 2007; Kuo et al., 2007; Howell, 2010). Copper is an important micronutrient, 
and copper transporters facilitate copper introduction into cells. Copper transporters 1 & 2 
(CTR1, CTR2) are generally thought to be copper’s main method of entry into the cell (Blair et 
al., 2009). Notably, CTR1 and CTR2 are also thought to transport cisplatin into cells (Kuo et al., 
2007; Blair et al., 2009; Howell, 2010). ATP7A and ATP7B are copper transporters that 
transport copper out of cells. Rabik et al. (2009) demonstrated increased activation of ATP7A 
and ATP7B appeared to correlate with increased removal of cisplatin out of cells. Both 
Matsumoto et al. (2007) and Holzer et al. (2004) found that treatment with CuSO4 (copper 
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sulfate) leads to increased cellular uptake of cisplatin, particularly in cisplatin-resistant cell lines. 
Published studies have investigated the interactions of CuSO4 and cisplatin primarily in 
laboratory-generated human cell lines. Matsumoto et al. (2007) utilized human epidermoid 
cancer cell lines with varying amounts of cisplatin-resistance, while Holzer et al. (2004) 
investigated the affect of CuSO4 administration on ovarian carcinoma cell lines. It is proposed 
that investigating the role of CuSO4 on cisplatin ototoxicity in vitro using the utricular epithelium 
of post-hatch chicks will provide a more controlled testing environment.  
Inhibition of vanilloid receptors 
Capsaicin is known to activate vanilloid receptors, which have been identified in the 
inner ear (Zheng et al., 2003). Vanilloid receptor Transient Receptor Potential Vanilloid 1 
(TRPV1) is expressed in hair and supporting cells in the organ of Corti. It has been shown that 
TRPV1 is activated by Reactive Oxygen Species (ROS) formation, which has been linked to 
ototoxicity (Clerici et al., 1995; Mukherjea et al., 2008). Vanilloid receptors can be blocked 
using capsazepine, an antagonist to capsaicin. Mukherjea et al. (2008) found that the inhibition 
of TRPV1 using the antagonist capsazepine reduced the ototoxic effects of cisplatin 
administration, thus suggesting a link between activation of TRPV1 and cisplatin ototoxicity. 
However, that study used an immortalized cell line in vitro, as well as living rats. It is believed 
that performing an in vitro study using utricle epithelium from post-hatch chicks will provide a 
more realistic and controlled basis for evaluating the effect of TRPV1 inhibition on the ototoxic 
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Regulation of apoptosis through MAPKs 
 Zine & van de Water (2004) note the importance of identifying regulatory components of 
apoptosis to better develop methods of preventing cell death. Mitogen activated protein kinases 
(MAPKs) have been identified as regulators of apoptosis (Gallo & Johnson, 2002; Zine & van de 
Water, 2004; Yang et al., 1997) and are comprised of c-Jun amino-terminal kinases (JNK), p-38 
kinases, and extracellular-signal-regulated kinases (ERK) (Bozyczko-Coyne et al., 2002). Many 
studies have shown that JNK activation leads to increased apoptosis in damaged cells (Eshraghi 
et al., 2007; Zine & Van De Water, 2004; Marderstein et al., 2003; Ylikoski et al., 2001; Pirvola, 
2000; Tournier et al., 2000; Yang et al., 1997). JNK has been reported to phosphorylate and 
activate the transcription factor c-Jun (Derijard et al., 1994). Behrens et al. (1999) have identified 
c-Jun as being the mitigating factor in apoptosis in JNK-activated cells for kainite-induced 
apoptosis and Scarpidis et al. (2003) determined the JNK/c-Jun pathway has a direct relationship 
with apoptosis. In the present study, we hypothesize that c-Jun plays a vital role in the initiation 
of cellular apoptosis following cisplatin-ototoxicity.  
Purpose of present study: The present study tests three previously proposed facets of cisplatin 
ototoxicity at the cellular level. Specifically, we examined the copper transport cycle with 
administration of CuSO4, the role of the TRPV1 gene via inhibition with capsazepine, and the 
interaction with c-Jun by the inhibition of the JNK pathway.  
Methods and materials 
Preparation of cultures: Epithelial cultures were prepared by Judy Speck in Dr. Mark Warchol’s 
laboratory. All protocols were approved by Washington University Institutional Animal 
Research Committee (Saint Louis, MO). In brief,  post-hatch (D7-21) chickens (Charles River 
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Laboratories) were euthanized utilizing CO2 asphyxiation and decapitated. Surface pathogens 
were removed using 70% EtOH for 5-10 minutes, and utricles were removed from exposed 
temporal bones and placed in chilled Medium 199 (M199) with Hanks’ salts and HEPES buffer. 
Utricles were then transferred to Thermolysin (500 μg/ml in M199) and incubated for 1 hour at 
37°C, then replaced with M199. Otoconia were removed at this time. Cultures were then 
transferred to culture wells (MatTek) and the epithelial layer was removed using a syringe 
needle. Earles M199 was placed in each well to cover culture, and cultures were incubated and 
fed fresh M199 for a period of 2-3 days. 
Immunohistochemistry: Prepared cultures were treated according to the specific needs of the 
study. For experiments involving the copper pathway, a solution of M199 with 10% Fetal Bovine 
Solution (FBS) with 20 μM cisplatin was added to all cultures. CuSO4 (1:50 at 2.5mM) was also 
immediately added to test cultures, though omitted from control cultures. Experiments involving 
TRPV1 required the treatment of a solution containing capsazepine. Medium 199 with 10% FBS 
with capsazepine (1:10) and Dimethyl sulfoxide (DSMO) (1:10) was further diluted, resulting in 
a final concentration of 10 μM capsazepine or 0.1% DSMO with medium 199. Cultures were 
treated with either this mixture or one containing no capsazepine (controls) and allowed to 
incubate for 30 minutes. After this period, 2 μL of concentrated cisplatin was added to all treated 
cells. Experiments that examined inhibition of the c-Jun pathway used a solution consisting of 
medium 199 with 10% FBS with 15μM SP600125 (dissolved in DSMO). Cultures were treated 
with either this mixture or one containing no SP600125 and allowed to incubate for 30 minutes 
before concentrated cisplatin (1:50) was added to all cells. 
To determine the effects of the various inhibitors on cisplatin toxicity, we calculated an 
apoptotic index (AI) for the various cultures. The AI is defined as the proportion of cells 
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undergoing programmed cellular death following injury. Cell death was assessed using 
immunohistochemistry. Following the various treatments, the cultures were incubated for an 
additional 24 hours and then fixed with 4% paraformaldehyde (20 minutes at room temperature) 
and rinsed with phosphate buffered saline (PBS) 5 times over 15 minutes. Cultures were treated 
in a blocking solution of PBS with 0.2% Triton X-100 and 5% normal horse serum (NHS) for 2 
hours prior to exposure to primary antibodies. Hair cells were identified with the HCS-1 
antibody and apoptotic cells were labeled via immunoreactivity for activated caspase-3. A 
solution consisting of PBS combined with 0.2% Triton, Mouse IgG HCS-1 Otoferlin (1:500), 
Rabbit IgG Activated Caspase-3 (1:100), and 2% NHS were added to each well of cultures. After 
being incubated for 24 hours at 4°C, the solution was removed and a solution consisting of PBS 
combined with 0.2% triton X-100 and secondary antibodies Alexa 488 (1:500) (for hair cell 
identification), Cy3 (Anti-rabbit) (1:500) (for apoptotic cell identification), and DAPI (1:500) 
(for identification of cell nuclei) was added to each well for a period of 2 hours at room 
temperature. After rinsing 5 times over 15 minutes with PBS, mounting solution (glycerol with 
PBS (1:10)) was added and each well was cover-slipped.  
Prior to investigating the effects of SP600125 on cisplatin-treated chick utricular cultures, 
we characterized the activation of the three MAPK pathways (JNK, p38, and ERK) in response 
to cisplatin treatment. This was accomplished by treating prepared cultures with medium 199 
with 10% FBS and 20 μM of concentrated cisplatin. Control cultures were treated with only 
medium 199 with 10% FBS. After 24 hours of incubation, cultures were then fixed with 4% 
paraformaldehyde (20 minutes at room temperature) and rinsed with PBS 5 times over 15 
minutes. Cultures were treated in a blocking solution of PBS with Triton X-100 (1:500) and NHS 
for 2 hours prior to exposure to primary antibodies. Following blocking, a solution consisting of 
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PBS combined with Triton (1:500), Rabbit IgG Activated Caspase-3 (1:100), NHS (1:50), and 
either Rabbit mAb p44/42 (ERK1/2) (1:500), Rabbit Ab P-p38 (1:500), or Rabbit Ab P-c-Jun 
(S63) (1:500) were added to each well of cultures, depending on intended investigation. 
Following incubation for 24 hours at 4°C, each solution was removed and a solution consisting 
of PBS combined with triton X-100 (1:500) and secondary antibodies Alexa 488 (1:500), Cy3 
(Anti-rabbit) (1:500), and DAPI (1:500) was added to each well for a period of 2 hours at room 
temperature. After rinsing 5 times over 15 minutes with PBS, mounting solution (glycerol with 
PBS (1:10)) was added and each well was cover-slipped. 
Imaging: Following immunohistochemical labeling, imaging was completed using a Zeiss 
Confocal microscope (LSM700) with a 20x objective. Two separate images identified through 
DAPI labeling were obtained utilizing Z-stacking per well of prepared cultures.  
Quantification: Processed specimens were imaged using the Volocity imaging program. Each 
image’s contrast was manually enhanced prior to quantification. Hair cell AI was determined by 
manual quantification of Cy3-labeled cells that were also labeled for Alexa 488. Total AI was 
determined by quantification of Cy-3 labeled cells as well as cell nuclei labeled with DAPI. Data 
were organized in a spreadsheet using Microsoft Excel and statistical analyses were performed.   
Statistics: Significance was identified by utilizing a Student t-Test. Standard deviations were 









CuSO4 to cisplatin-treated 
cultures of chick utricle 
epithelium significantly 
increased the apoptotic 
index (AI) of hair cells. 
The mean AI for CuSO4 
treated cells was 0.59 
±0.28, while the mean AI 
for control cultures was 
0.43 ±0.36 (Figure 1, 
images 1 & 2). A Student’s 
t-test demonstrated 
statistical significance at the 


















Figure 1 (upper left). Quantification of chick 
utriclar epithelium treated with CuSO4
simultaneous with cisplatin administration  
(23 specimens, 41 images obtained) 
compared to control population (24 
specimens, 46 images obtained) with same 
cisplatin dosage revealed statistically 
significant (<0.05) increase in apoptosis in 
treated cells.  Image 1 (upper right). CuSO4 
administration; hair cells labeled with Alexa
488 (green), apoptotic cells labeled with 
Cy3 (red). Image 2 (lower left). Control 
culture; hair cells labeled with Alexa 488 
























Figure 2 (upper left). Quantification of chick 
utriclar epithelium treated with capsazepine 
prior to cisplatin administration (11 
specimens, 22 images obtained) compared to 
control (9 specimens, 17 images obtained) 
with same cisplatin dosage revealed 
statistically significant (<0.005) decrease in 
apoptosis in treated cells. Image 3 (upper 
right). Capsazepine administration; hair cells 
labeled with Alexa 488 (green), apoptotic 
cells labeled with Cy3 (red). Image 4 (lower 
left). Control culture; hair cells labeled with 
Alexa 488 (green), apoptotic cells labeled 
with Cy3 (red). 
In contrast, 
application of capsazepine 
to post-hatch chick utricular 
epithelium prior to 
treatment with cisplatin 
caused a decrease in cell 
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Figure 3 (Upper left). Quantification of 
cisplatin-treated cells (5 specimens, 9 images 
obtained) compared to controls (5 specimens, 
10 images obtained), labeled for p38 expression 
revealed no significant differences between the 
two groups. Image 5 (upper right). Cisplatin 
treated culture labeled for p38 expression; all 
cell nuclei labeled with DAPI (blue), p38-
expressed cells labeled with Cy3 (red). Image 6 
(lower left). Control culture labeled for p38 
expression; all cell nuclei labeled with DAPI 
(blue), p38-expressed cells labeled with Cy3 
(red). 
death compared to controls. 
While control cultures had 
a mean AI of 0.49 ±0.15, 
treated cultures had a 
significantly smaller mean 
AI of 0.30 ±0.20 (Figure 2, 
images 3 & 4). This was 
shown to be statistically 
significant to the <0.005 
























Figure 4 (upper left). Quantification of 
cisplatin-treated cells (6 specimens, 11 images 
obtained) compared to control population (6 
specimens, 12 images obtained), labeled for 
ERK expression revealed statistically 
significant decrease in apoptosis in cisplatin-
treated cells (<0.05).  Image 7 (upper right). 
Cisplatin treated culture labeled for ERK 
expression; a ll cell nuclei labeled with DAPI 
(blue), ERK-expression labeled with Cy3 
(red). Image 8 (lower left). Control culture 
labeled for ERK expression; a ll cell nuclei 
labeled with DAPI (blue), ERK expression 
labeled with Cy3 (red). 
 Following 
preliminary investigations 
of the effects of inhibiting 
c-Jun on apoptosis in the 
chick utricle, labeled cell 
counts were obtained for 
all cells with activated p38 
and ERK1/2, as well as P-
c-Jun. For P-c-Jun labeled 
cells, a labeled hair cell 
count was also obtained. 
Statistical analyses revealed a labeled cell count of 0.69 ±0.24 for cisplatin-treated cells labeled 
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for p38 verses 0.59 ±0.30 
for control cells. This was 
not statistically significant 
(Figure 3, images 5 & 6). 
For ERK-labeled cells 
treated with cisplatin, the 
calculated labeled cell 
count was 0.31 ±0.30 for 
treated cells, and 0.62 
±0.40 for control cells, 
which was statistically 
significant (<0.05) (Figure 
4, images 7 & 8). c-Jun 
labeled cells treated with 
cisplatin revealed a labeled 
cell count of 0.65 ±0.27 
versus 0.26 ±0.17 in control 
cells, this difference was 
significant (<0.0005) 
























Figure 5 (upper left). Quantification of 
cisplatin-treated cells (7 specimens, 13 
images obtained) compared to control cells 
(6 specimens, 12 images obtained) labeled 
for C-Jun expression revealed a statistically 
significant increase in cisplatin-treated cells 
(<0.0005). Image 9 (upper right). Cisplatin 
treated culture labeled for P-c-Jun 
expression; all cell nuclei labeled with DAPI 
(blue), P-c-Jun expressed cells labeled with 
Cy3 (red). Image 10 (lower right). Control 
culture labeled for P-c-Jun expression; all 
cell nuclei labeled with DAPI (blue), P-c-Jun 

















Figure 6 (Upper left). Quantification of chick 
utriclar cultures treated with JNK inhibitor 
and labeled for P-c-Jun expression (10 
specimens, 19 images obtained) compared to 
control population  (12 specimens, 22 images 
obtained) revealed statistically significant 
decrease in AI in treated population (<0.05). 
Image 11 (Upper right). Cisplatin treated 
culture with JNK inhibitor; hair cells labeled 
with Alexa 488 (green), apoptotic cells 
labeled with Cy3 (red). Image 12 (Lower 
left). Control culture treated with cisplatin; 
hair cells labeled with Alexa 488 (green), 
apoptotic cells labeled with Cy3 (red). 
Based on these 
findings, we further 
investigated c-Jun’s role in cisplatin toxicity. Inhibition of JNK resulted in a hair cell AI of 0.09 
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±0.04 for treated cultures, 
compared to a hair cell AI of 
0.15 ±0.09 for control 
cultures, which was again 
statistically significant 
(<0.05) (Figure 6, images 11 
& 12). Analysis of the non-
hair cell specific AI yielded 
0.05±0.04 for treated cells 
and 0.07±0.05 for control 
cells. This difference was not 
significant (Figure 7, images 
















Figure 7 (Upper left). Quantification of 
cisplatin-treated chick utriclar cultures 
labeled for P-c-Jun expression and treated 
with JNK inhibitor (10 specimens, 19 
images obtained) compared to control 
populations (12 specimens, 22 images 
obtained). Image 13 (upper right). Cisplatin 
treated cells with JNK inhibitor 
administration; all cell nuclei labeled with 
DAPI (blue), apoptotic cells labeled with 
Cy3 (red). Image 14 (lower left). Control 
cultures with cisplatin administration; a ll 
cell nuclei labeled with DAPI (blue), 
apoptotic cells labeled with Cy3 (red). 
Discussion 
Treatment with copper sulfate 
Cisplatin-resistant cell lines have been noted to have cross-resistance to copper 
(Matsumoto et al., 2007). Interfering with copper transporters using CuSO4 has been proposed to 
increase cisplatin intake into the cell. In the present study, CuSO4 was administered 
simultaneously with cisplatin to cultures of chick utricular epithelium. Results agree with some 
previous studies, and showed increased apoptosis in CuSO4-treated cells compared to controls. 
The present work extends previous findings in cell lines to avian utricles. Theories on the 
relation between increased CuSO4 and apoptosis involve the transport of copper into and out of 
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the cell. Since increased levels of apoptosis likely indicate increased levels of cisplatin remain in 
the cell, it is possible that the ATP7A and ATP7B transporters are more efficient at removing 
cisplatin from the cell in control (i.e. non-CuSO4-treated) cultures. It is likely that the influx of 
CuSO4 may saturate the cell and subsequently reduce ATP7A and ATP7B-mediated efflux of 
cisplatin. Demonstration of a positive relationship between cell death and increased copper 
transport could potentially lead to the development of new therapeutic drugs to prevent cisplatin 
ototoxicity. Further research is required to confirm similar effects of CuSO4 on avian utricle and 
mammalian utricle and cochlea.  
TRPV1 inhibition 
The second phase of the current study investigated the effects of inhibiting TRPV1 using 
the capsaicin antagonist capsazepine. Mukherjea et al. (2008) previously demonstrated that 
TRPV1 inhibition reduced apoptosis following cisplatin administration. Results from the current 
study agree with Mukherjea’s data; avian utricular epithelia treated with capsazepine resulted in 
30%±20% of hair cells undergoing apoptosis, compared to 49%±15% in control cultures. 
Because the TRPV1 gene is activated by multiple stimuli (both chemical and non-chemical), 
potential contraindications of inhibiting activation of the gene must be researched and 
considered. Further research applying in-vitro and in-vivo avian and mammalian models is 
needed to further explore the role of TRPV1 inhibition as a clinical strategy. 
MAPK pathways   
The third phase of the current study investigated the connection between MAPK 
pathways (p38, ERK1/2, JNK) and apoptosis following cisplatin administration. Identifying the 
level of MAPK activation in cisplatin-treated cells compared to controls revealed that 69% ±24% 
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of cisplatin-treated cells displayed activated p38, compared to 59% ±30% in control cells (not 
statistically significant); 31% ±30% of cisplatin-treated cells displayed activated ERK compared 
to 62% ±40% in control cells (statistically significant, <0.05); and 65% ±27% of cisplatin-treated 
cells displayed activated P-c-Jun compared to 26% ±17% in control cells (statistically 
significant, <0.0005). In addition, inhibiting JNK in cisplatin-treated cell cultures revealed 9% of 
hair cells undergoing apoptosis compared to 15% in control cultures (statistically significant, 
<0.05), and 5% of all cells (hair cells and supporting cells) were apoptotic in JNK-inhibited 
cultures, compared to 7% in control cell cultures (not statistically significant). The present results 
confirm previous results in other model systems demonstrating that inhibition of JNK decreases 
hair cell apoptosis (Eshraghi et al., 2007; Zine & Van De Water, 2004; Marderstein et al., 2003; 
Ylikoski et al., 2001; Pirvola, 2000; Tournier et al., 2000; Yang et al., 1997). Studies to date do 
not resolve whether the role of JNK is the same in hair cells and supporting cells. Further 
research should also address whether our observations in post-hatch chick utricle culture 
correspond to those in mammalian organ culture systems. Finally, given that we observed a 
significant decrease in apoptosis in cisplatin-treated ERK-labeled cells, future studies should 
investigate the relationship between inhibition of the ERK pathway and cisplatin treatment.  
Conclusion 
Multiple parallel cellular mechanisms mediate cisplatin ototoxicity. We show that 
CuSO4, capsazepine, and SP600125 all significantly alter the amount of apoptosis in post-hatch 
chick utricle hair cells. While this is most certainly not an exhaustive list of potential pathways 
of cellular uptake, further investigation into these pathways will be essential to 
determinepossible clinical applications of the inhibitors tested above.  
12 
 
  Yarnell 
 
Bibliography 
Behrens, A., Sibilia, M., & Wagner, E. F. (1999). Amino-terminal phosphorylation of c-Jun 
regulates stress-induced apoptosis and cellular proliferation. Nature Genetics , 21, 326-
329. 
Blair, B. G., Larson, C. A., Safaei, R., & Howell, S. B. (2009). Copper Tranporter 2 Regulates 
the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin. Clinical 
Cancer Research , 15, 4312-4321. 
Bozyczko-Coyne, D., Saporito, M. S., & Hudkins, R. L. (2002). Targeting the JNK Pathway for 
Therapeutic Benefit in CNS Disease. Current Drug Targets - CNS & Neurological 
Disorders , 1, 31-49. 
Clerici, W. J., DiMartino, D. L., & Prasad, M. R. (1995). Direct effects of reactive oxygen 
species on cochlear outer hair cell shape in vitro. Hearing Research , 84, 30-40. 
Derijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., et al. (1994). JNK1: A Protein 
Kinase Stimulated by UV Light and Ha-Ras that Binds and Phosphorylates the c-Jun 
Activation Domain. Cell , 76, 1025-1037. 
Eshraghi, A. A., Wang, J., Adil, E., He, J., Zine, A., Bublik, M., et al. (2006). Blocking c-Jun-N-
terminal kinase signaling can prevent hearing loss induced by both electrode insertion 
trauma and neomycin ototoxicity. Hearing Research , 226, 168-177. 
Gallo, K. A., & Johnson, G. L. (2002). Mixed-Lineage Kinase Control of JNK and p38 MAPK 
Pathways. Molecular Cell Biology , 3, 663-672. 
Holzer, A. K., Samimi, G., Katano, K., Naerdemann, W., Lin, X., Safaei, R., et al. (2004). The 
Copper Influx Transporter Copper Transport Protein 1 Regulates the Uptake of Cisplatin 
in Human Ovarian Carscinoma Cells. Molecular Pharmacology , 66, 817-823. 
13 
 
  Yarnell 
 
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010). Copper Transporters and the 
Cellular Pharmacology of the Platinum-Containing Cancer Drugs. Molecular 
Pharmacology , 77, 887-894. 
Kuo, M. T., Chen, H. H., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007). The roles of copper 
tranporters in cisplatin resistance. Cancer Metastasis Review , 26, 71-83. 
Marderstein, E. L., Bucher, B., Guo, Z., Feng, Z., Reid, K., & Geller, D. A. (2003). Protection of 
rat hepatozytes from apoptosis by inhibition of c-Jun N-Terminal kinase. Surgery , 280-
284. 
Matsumoto, S., Tanaka, T., Kurokawa, H., Matsuno, K., Hayashida, Y., & Takahashi, T. (2007). 
Effect of Copper and Role of the Copper Transporters ATP7A and CTRL1 in 
Intracellular Accumulation of Cisplatin. Anticancer Research , 27, 2209-2216. 
Mukherjea, D., Jajoo, S., Whitworth, C., Bunch, J. R., Turner, J. G., Rybak, L. P., et al. (2008). 
Short Interfering RNA against Transient Receptor Potential Vanilloid 1 Attenuates 
Cisplatin-Induced Hearing Loss in the Rat. The Journal of Neuroscience , 28, 13056-
13065. 
Nagy, J. L., Adelstein, D. J., Newman, C. W., Rybicki, L. A., Rice, T. W., & Lavertu, P. (1999). 
Cisplatin ototoxicity: the importance of baseline audiometry. American Journal of 
Clinical Oncology , 22, 305-308. 
Pirvola, U., Xing-Qun, L., Virkkala, J., Saarma, M., Murakata, C., Camoratto, A. M., et al. 
(2000). Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an 




  Yarnell 
 
Rabik, C. A., Maryon, E. B., Kasza, K., Shafer, J. T., Bartnik, C. M., & Dolan, M. E. (2009). 
Role of copper transporters in resistance to platinating agents. Cancer Chemotherapy 
Pharmacological , 64, 133-142. 
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007). Mechanisms of 
cisplatin-induced ototoxicity and prevention. Hearing Research , 226, 157-167. 
Scarpidis, U., Madnani, D., Shoemaker, C., Fletcher, C. H., Kojima, K., Eshraghi, A. A., et al. 
(2003). Arrest of Apoptosis in Auditory Neurons: Implications for Sensorineural 
Preservation in Cochlear Implantation. Otology & Neurology , 24, 409-417. 
Slattery, E. L., & Warchol, M. E. (2010). Cisplatin Ototoxicity Blocks Sensory Regeneration in 
the Avian Inner Ear. The Journal of Neuroscience , 30, 3473-3481. 
Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., et al. (2000). 
Requirement of JNK for Stress-Induced Activation of the Cytochrome c-Mediated Death 
Pathway. Science , 288, 870-874. 
van Ruijven, M. W., de Groot, J. C., Klis, S. F., & Smoorenburg, G. F. (2005). The cochlear 
targets of cisplatin: An electrophysiological and morphological time-sequence study. 
Hearing Reserach , 205, 241-248. 
Wang, D., & Lippard, S. J. (2005). Cellular Processing of Platinum Anticancer Drugs. Nature 
Reviews , 4, 307-320. 
Yang, D. D., Kuan, C.-Y., Whitmarsh, A. J., Rincon, M., Zheng, T. S., Davis, R. J., et al. (1997). 
Absense of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 
gene. Nature , 389, 865-870. 
15 
 




Ylikoski, J., Xing-Qun, L., Virkkala, J., & Pirvola, U. (2002). Blockade of c-Jun N-terminal 
kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. 
Hearing Research , 166, 33-43. 
Zheng, J., Dai, C., Steyger, P. S., Kim, Y., Vass, Z., Ren, T., et al. (2003). Vanilloid Receptors in 
Hearing: Altered Cochlear Sensitivity by Vanilloids and Expression of TRPV1 in the 
Organ of Corti. Journal of Neurophysiology , 90, 444-455. 
Zine, A., & van de Water, T. R. (2004). The MAPK/JNK signalling pathway offers potential 
therapeutic targets for the prevention of acquired deafness. Current Drug Targets CNS 
Neuological Disorders , 3, 325-332. 
